|Articles|August 22, 2017

Sugars in Breast Milk Found to Have Antibacterial Properties

The results of a new study from Vanderbilt University provide more support for breastfeeding, revealing that sugars in human breast milk can help protect babies from bacterial infections.

Healthcare practitioners have longed encouraged new mothers to breastfeed their infants because breast milk has been shown to decrease infants’ risk of ear infections, asthma, and lower type 2 diabetes, among other conditions. Now, the results of a new study are providing more support for this practice, showing that the sugars in human breast milk can help protect babies from bacterial infections.

The proteins in human breast milk—which is a combination of proteins, fats, and sugars—have long been studied for their antibacterial properties; however, Steven Townsend, PhD, assistant professor, Chemistry, Vanderbilt University, and his team of chemists and doctors, decided to study the sugars. Dr. Townsend explained why, in a press release, “For most of the last century, biochemists have argued that proteins are most important and sugars are an afterthought. Most people have bought into that argument, even though there's no data to support it. Far less is known about the function of sugars and, as a trained glycoprotein chemist, I wanted to explore their role.”

For the pilot study, the researchers collected 5 samples of oligosaccharides, human milk carbohydrates, from several different donors. They profiled the samples using “a mass spectrometry technique that can identify thousands of large biomolecules simultaneously,” according to the press release. Afterwards, they added the samples to cultures of Group B strep bacteria—the leading cause of infections in newborns worldwide—and viewed the results under a microscope. Using this technique, the researchers found that the oligosaccharides are able to kill the bacteria as well as break down their biofilms. More specifically, they found that, “one sample nearly killed an entire strep colony,” one sample was moderately effective against the bacteria, and, “the remaining three samples exhibited a lower level of activity.” In addition, preliminary results from a follow-up study of 24 other samples has shown that, “two broke down the bacterial biofilms and killed the bacteria, for broke down the biofilms but did not kill the bacteria, and two killed the bacteria without breaking down the biofilms.”

When speaking about the results of the studies in the press release, Dr. Townsend said, “Our results show that these sugars have a one-two punch. First, they sensitize the target bacteria and then they kill them. Biologists sometimes call this 'synthetic lethality' and there is a major push to develop new antimicrobial drugs with this capability.”

The researchers were also able to show that, “sugars' ability to break down biofilms can also enhance the effectiveness of the other antimicrobial agents that breast milk contains, by dosing strep cultures with a mixture of milk sugars and antimicrobial peptides from human saliva.”

Additional follow-up studies have shown that the sugars in human breastmilk also show antimicrobial activity against 2 of the 6 ESKAPE pathogens, which are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species, according to the press release. These pathogens are the leading cause of nosocomial infections around the world.

Speaking about the implications of this research in the press release, Dr. Townsend remarked, “This is the first example of generalized, antimicrobial activity on the part of the carbohydrates in human milk. One of the remarkable properties of these compounds is that they are clearly non-toxic, unlike most antibiotics."

For future research, Dr. Townsend will be working with his, “colleagues in Vanderbilt's Mass Spectrometry Research Center to identify the specific types of carbohydrate molecules responsible for the antibacterial effects they have discovered.”

The results of the study were presented at the annual American Chemical Society meeting in Washington, DC, on August 20, 2017.


Related to this article

Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
Vibrio species are bacteria that live in saltwater environments. When ingested orally or through contact with open wounds, some species can cause severe life-threatening infections, particularly in those with high-risk conditions, such as liver disease. Here is a review of Vibrio vulnificus and the recommended antibiotic treatment.